CSL LTD (CSLLY) Stock
CSLLY has an Alpha Score of 35 out of 100 (weak), computed on Apr 15, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 3 trades in CSLLY since 2018: 1 purchase and 2 sales, most recently Daniel Goldman (sale, Jul 10, 2023).
What is CSLLY's Alpha Score?
How it works →Alpha Score of 35 reflects weak overall profile with poor momentum, strong value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Apr 15, 2026 · 189 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded CSL LTD (CSLLY)?
Most recent: Daniel Goldman (sale, Jul 10, 2023); records start Dec 7, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-07-10 | sale | $50k – $100k |
| Dan Goldman D-NY · House | 2023-02-27 | purchase | $15k – $50k |
| Greg Gianforte R-MT · House | 2018-12-07 | sale | $100k – $250k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all CSLLY political trades →What are CSLLY's key statistics?
Key statistics as of Oct 22, 2026
How does CSLLY's valuation compare with the Healthcare sector?
| Metric | CSLLY | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -16.33% | 9.40% | 92 |
| Return on equity | -15.42% | 11.24% | 99 |
| Dividend yield (payers) | 1.23% | 1.62% | 46 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Oct 22, 2026). P/E excludes loss-making companies.
CSLLY price chart
Powered by TradingViewWhat does CSL LTD do?
CSL Limited Sponsored ADR represents shares of the Australian biotechnology company CSL Limited that are traded on American stock exchanges. CSL Limited is renowned for its focus on developing and manufacturing innovative biopharmaceutical products, especially in the fields of immunotherapy and protein-based therapies. The company's product portfolio includes a wide range of medicines used to treat bleeding disorders, immune deficiencies, and neurological disorders, serving critical medical needs globally. By issuing sponsored ADRs, CSL Limited extends its reach to U.S. investors, allowing them to access its shares without needing to purchase them directly on Australian exchanges. This ADR plays a significant role in expanding the company’s investor base, thereby increasing its capital inflows and enhancing liquidity. CSL's operations greatly impact the healthcare sector, providing advanced therapeutics that drive progress in medical science and improve patient outcomes around the world. As a leader in the biotechnology industry, CSL is committed to sustaining its growth through R&D and strategic expansion, solidifying its position as a key player in the global pharma and biotech markets.